Skip to main content
Premium Trial:

Request an Annual Quote

Waters, Reactome, Thermo Electron, Peter Leddy, Greg Lucier, Bill Castell, Thomas McLain

Premium

New Products

Waters has released MarkerLynx db Application Manager, a metabonomics and biomarker data management tool for its MassLynx 4.1 statistical analysis and database searching software. MarkerLynx db Application Manager offers improved peak detection, enhanced statistical tools, and new dynamic database searching and storage capabilities for the identification of biomarkers, the company said.


Reactome version 14 is available at http://www.reactome.org. New modules and subsections include post-translational modification of proteins, notch signaling, and hormone-sensitive lipase added under lipid metabolism; mitochondrial transcription added under transcription; MAPK cascade added under insulin receptor mediated signaling; and polo-like kinases added under cell cycle, mitosis.


Thermo Electron has released version 7.0 of its Nautilus LIMS for early-stage discovery. Nautilus includes a new archiving function that enables users to automatically transfer data from active tables to archived tables and back again.

 

Movers & Shakers

Peter Leddy will join Invitrogen as senior vice president of human resources effective July 5. He most recently served as vice president of human resources for the Americas operations of Dell. Leddy will oversee Invitrogen's global HR strategy and report directly to CEO Greg Lucier


General Electric said that Bill Castell, CEO of GE Healthcare, will retire next year. He will be replaced by Joe Hogan upon his retirement. The appointment was included in an announcement about the realigning of GE's businesses.


Thomas McLain has been appointed to the board of directors of the Biotechnology Industry Organization, effective June 21, 2005. McLain is one of 11 new board members, who will each serve two-year terms.

McLain is currently the chairman, CEO and president of Nabi Pharmaceuticals. Prior to joining Nabi Pharmaceuticals in 1998, McLain was employed by Bausch & Lomb.

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.